Jiangsu Alphamab Oncology-B(09966.HK): Phase II Clinical Trial of JSKN033 as First-line Therapy for Advanced Cervical Cancer Completes First Patient Dosing

NewTimeSpace News: On May 13, 2026, Jiangsu Alphamab Oncology-B(09966.HK) issued a voluntary announcement stating that the Phase II clinical trial (JSKN033-202) of JSKN033 combined with platinum-based chemotherapy, with or without bevacizumab, for the first-line treatment of advanced cervical cancer has completed the first patient dosing.

According to the announcement, JSKN033 is the world’s first high-concentration subcutaneous injectable combination formulation developed by Alphamab Oncology. It consists of JSKN003, a HER2 bispecific ADC, and envafolimab, a PD-L1 domain antibody. It features differentiated advantages including seconds-level subcutaneous administration and low haematological toxicity.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.